Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Arjun Pandey(University of Ottawa), Subodh Verma(St. Michael's Hospital), Ambarish Pandey(Cleveland Clinic), Deepak L. Bhatt(Mount Sinai Hospital), Francesco Cosentino(Linköping University), Avinash Pandey(University of Ottawa), Nikolaus Marx(RWTH Aachen University)
Cited by 92
Related Papers
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
|Circulation|2019|9.1k
Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
|Circulation|2018|7.2k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k